Search

Your search keyword '"Stephan Mose"' showing total 746 results
Start Over Author "Stephan Mose"
746 results on '"Stephan Mose"'

1. A nested case-control study on radiation dose-response for cardiac events in breast cancer patients in Germany

Author

Dan Baaken, Hiltrud Merzenich, Marcus Schmidt, Inga Bekes, Lukas Schwentner, Wolfgang Janni, Achim Wöckel, Manfred Mayr, Stephan Mose, Thomas Merz, Voica Ghilescu, Jona Renner, Detlef Bartkowiak, Thomas Wiegel, Maria Blettner, Heinz Schmidberger, and Daniel Wollschläger

Subjects
Breast cancer, Radiotherapy, Cardiac mortality, Cardiac morbidity, Nested case-control study, Dose-response analysis, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Background: Previous studies with the majority of breast cancer (BC) patients treated up to 2000 provided evidence that radiation dose to the heart from radiotherapy (RT) was linearly associated with increasing risk for long-term cardiac disease. RT techniques changed substantially over time. This study aimed to investigate the dose-dependent cardiac risk in German BC patients treated with more contemporary RT. Methods: In a cohort of 11,982 BC patients diagnosed in 1998–2008, we identified 494 women treated with 3D-conformal RT who subsequently developed a cardiac event. Within a nested case-control approach, these cases were matched to 988 controls. Controls were patients without a cardiac event after RT until the index date of the corresponding case. Separate multivariable conditional logistic regression models were used to assess the association of radiation to the complete heart and to the left anterior heart wall (LAHW) with cardiac events. Results: Mean dose to the heart for cases with left-sided BC was 4.27 Gy and 1.64 Gy for cases with right-sided BC. For controls, corresponding values were 4.31 Gy and 1.66 Gy, respectively. The odds ratio (OR) per 1 Gy increase in dose to the complete heart was 0.99 (95% confidence interval (CI): 0.94–1.05, P = .72). The OR per 1 Gy increase in LAHW dose was 1.00 (95% CI: 0.98–1.01, P = .68). Conclusions: Contrary to previous studies, our study provided no evidence that radiation dose to the heart from 3D-conformal RT for BC patients treated between 1998 and 2008 was associated with risk of cardiac events.

Published
2022
Full Text
View/download PDF

2. Target Attainment and Population Pharmacokinetics of Cefazolin in Patients with Invasive Staphylococcus aureus Infections: A Prospective Cohort Study

Author

Severin Bausch, Sarah Dräger, Panteleimon Charitos-Fragkakis, Adrian Egli, Stephan Moser, Vladimira Hinic, Richard Kuehl, Stefano Bassetti, Martin Siegemund, Katharina M. Rentsch, Laura Hermann, Verena Schöning, Felix Hammann, Parham Sendi, and Michael Osthoff

Subjects
Staphylococcus aureus, cefazolin, therapeutic drug monitoring, target attainment, population pharmacokinetic model, Therapeutics. Pharmacology, RM1-950
Abstract

This study aimed to determine cefazolin target attainment in patients with invasive Staphylococcus aureus (S. aureus) infections and to develop a population pharmacokinetic (PK) model. Adult patients with invasive S. aureus infections treated with cefazolin bolus infusions were included. Unbound and total trough and mid-dose cefazolin concentrations were measured, and strain-specific MICs were determined. The primary outcome was the proportion of patients attaining 100% fT>MIC at all time points evaluated. A population PK model was developed, using non-linear mixed-effects modelling. Overall, 51 patients were included, with a total of 226 unbound and total cefazolin concentrations measured (mean: 4.4 per patient). The median daily dosage in patients with an estimated glomerular filtration rate of >60 mL/min/m2 was 8 g. The median age was 74 years (interquartile range (IQR) 57–82) and 26% were female. A history of chronic kidney disease and acute kidney injury were present in 10/51 (19.6%) and 6/51 (11.7%), respectively. Achievement of 100% fT>MIC occurred in 86% of the patients and decreased to 45% when a target of 100% fT>4xMIC was evaluated. The mean unbound cefazolin fraction was 27.0% (standard deviation (SD) 13.4). Measured and estimated mean cefazolin trough concentrations differed significantly [13.1 mg/L (SD 23.5) vs. 7.4 mg/L (SD 7.9), p < 0.001]. In the population PK model, elevated estimated creatinine clearance and bolus instead of continuous application were covariates for target non-attainment. In conclusion, cefazolin target achievement was high, and the measurement of the unbound cefazolin concentration may be favored. The Monte Carlo simulations indicated that target attainment was significantly improved with continuous infusion.

Published
2024
Full Text
View/download PDF

3. Association of Endothelial Cell Activation with Acute Kidney Injury during Coronary Angiography and the Influence of Recombinant Human C1 Inhibitor—A Secondary Analysis of a Randomized, Placebo-Controlled, Double-Blind Trial

Author

Stephan Moser, Laura Araschmid, Anneza Panagiotou, Leo H. Bonati, Tobias Breidthardt, Gregor Fahrni, Christoph Kaiser, Raban Jeger, Marten Trendelenburg, and Michael Osthoff

Subjects
endothelial cell activation, complement system, C1 inhibitor, contrast media, ICAM-1, VCAM-1, Biology (General), QH301-705.5
Abstract

Background: Acute kidney injury (AKI) as a result of iodinated contrast media (CM) has been linked to CM-induced renal ischemia and toxic effects on endothelial cells (EC). The recombinant human C1 inhibitor (rhC1INH) has been shown to influence EC activation. Methods: Secondary analysis of 74/77 (96%) participants of a double-blind, randomized, and placebo-controlled study that assessed the effect of rhC1INH on AKI. E-selectin, intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule (VCAM-1), and CC-chemokin-ligand-5 (CCL5) were determined in frozen blood samples over 48 h and analyzed according to the treatment group and renal outcomes. Results: The mean age was 76.7 years, and 37 patients each received rhC1INH and placebo, respectively. In the entire study population, minor differences in median EC activation markers/CCL5 concentrations during the first 48 h compared to baseline were observed (e.g., E-selectin 27.5 ng/mL at baseline vs. 29.7 ng/mL on day 1, CCL5: 17.7 ng/mL at baseline vs. 32.2 ng/mL on day 2). Absolute changes in ICAM-1/E-selectin concentrations correlated with a higher peak change in urinary NGAL concentrations. However, AKI was not associated with significant changes in EC markers/CCL5. Last, no significant differences in serum concentrations of EC activation markers/CCL5 were evident between the placebo and the rhC1INH group. Conclusions: CM administration during coronary angiography only mildly activated ECs within the first 48 h, which does not explain subsequent AKI. The administration of rhC1INH was not associated with a reduction of EC activation or CCL5.

Published
2024
Full Text
View/download PDF

4. Recombinant C1 inhibitor in the prevention of severe COVID-19: a randomized, open-label, multi-center phase IIa trial

Author

Pascal Urwyler, Marina Leimbacher, Panteleimon Charitos, Stephan Moser, Ingmar A. F. M. Heijnen, Marten Trendelenburg, Reto Thoma, Johannes Sumer, Adrián Camacho-Ortiz, Marcelo R. Bacci, Lars C. Huber, Melina Stüssi-Helbling, Werner C. Albrich, Parham Sendi, and Michael Osthoff

Subjects
COVID-19, randomized trial, C1 esterase inhibitor, complement system, kallikrein kinin system, contact activation system, Immunologic diseases. Allergy, RC581-607
Abstract

BackgroundConestat alfa (ConA), a recombinant human C1 inhibitor, may prevent thromboinflammation.MethodsWe conducted a randomized, open-label, multi-national clinical trial in which hospitalized adults at risk for progression to severe COVID-19 were assigned in a 2:1 ratio to receive either 3 days of ConA plus standard of care (SOC) or SOC alone. Primary and secondary endpoints were day 7 disease severity on the WHO Ordinal Scale, time to clinical improvement within 14 days, and safety, respectively.ResultsThe trial was prematurely terminated because of futility after randomization of 84 patients, 56 in the ConA and 28 in the control arm. At baseline, higher WHO Ordinal Scale scores were more frequently observed in the ConA than in the control arm. On day 7, no relevant differences in the primary outcome were noted between the two arms (p = 0.11). The median time to defervescence was 3 days, and the median time to clinical improvement was 7 days in both arms (p = 0.22 and 0.56, respectively). Activation of plasma cascades and endothelial cells over time was similar in both groups. The incidence of adverse events (AEs) was higher in the intervention arm (any AE, 30% with ConA vs. 19% with SOC alone; serious AE, 27% vs. 15%; death, 11% vs. 0%). None of these were judged as being related to the study drug.ConclusionThe study results do not support the use of ConA to prevent COVID-19 progression.Clinical trial registrationhttps://clinicaltrials.gov, identifier NCT04414631.

Published
2023
Full Text
View/download PDF

5. Radiation Therapy in Kaposi’s Sarcoma

Author

Stephan Mose

Subjects
Radiation therapy, business.industry, medicine.medical_treatment, medicine, Cancer research, medicine.disease, business, Kaposi's sarcoma
Published
2017

6. In Vivo Dosimetry with Semiconducting Diodes for Dose Verification in Total-Body Irradiation

Author

Christian Scherf, E. Kara, Stephan Mose, Jörg Licher, Jussi Moog, U. Ramm, Claus Rödel, and Heinz-Dietrich Böttcher

Subjects
business.industry, Radiotherapy Planning, Computer-Assisted, medicine.medical_treatment, Equipment Design, Total body irradiation, Radiotherapy, High-Energy, Radiation therapy, Radiation Protection, Semiconductors, Oncology, medicine, Dose verification, Calibration, Humans, Dosimetry, Radiology, Nuclear Medicine and imaging, Dose Fractionation, Radiation, Tomography, Radiometry, In vivo dosimetry, business, Nuclear medicine, Lung, Whole-Body Irradiation, Diode
Abstract

Background and Purpose: For total-body irradiation (TBI) using the translation method, dose distribution cannot be computed with computer-assisted three-dimensional planning systems. Therefore, dose distribution has to be primarily estimated based on CT scans (beam-zone method) which is followed by in vivo measurements to ascertain a homogeneous dose delivery. The aim of this study was to clinically establish semiconductor probes as a simple and fast method to obtain an online verification of the dose at relevant points. Patients and Methods: In 110 consecutively irradiated TBI patients (12.6 Gy, 2 × 1.8 Gy/day), six semiconductor probes were attached to the body surface at dose-relevant points (eye/head, neck, lung, navel). The mid-body point of the abdomen was defined as dose reference point. The speed of translation was optimized to definitively reach the prescribed dose in this point. Based on the entrance and exit doses, the mid-body doses at the other points were computed. The dose homogeneity in the entire target volume was determined comparing all measured data with the dose at the reference point. Results: After calibration of the semiconductor probes under treatment conditions the dose in selected points and the dose homogeneity in the target volume could be quantitatively specified. In the TBI patients, conformity of calculated and measured doses in the given points was achieved with small deviations of adequate accuracy. The data of 80% of the patients are within an uncertainty of ± 5%. Conclusion: During TBI using the translation method, dose distribution and dose homogeneity can be easily controlled in selected points by means of semiconductor probes. Semiconductor probes are recommended for further use in the physical evaluation of TBI.

Published
2008

7. The Burden of Pain of Inpatients Undergoing Radiotherapy – Discrepancies in the Ratings of Physicians and Nurses

Author

Francisco de la Fuente, K. Budischewski, Stephan Mose, and Corinna E.E. Nierhoff

Subjects
Adult, Cancer Research, medicine.medical_specialty, medicine.medical_treatment, Nurses, Pain, Sensitivity and Specificity, Germany, Neoplasms, Physicians, Surveys and Questionnaires, medicine, Humans, Aged, Pain Measurement, Aged, 80 and over, Inpatients, Radiotherapy, business.industry, Reproducibility of Results, Cancer, Hematology, Middle Aged, medicine.disease, Radiation therapy, Oncology, Family medicine, business
Abstract

The aim of this study was to rate the burden of pain of cancer patients receiving radiotherapy from the point of view of the patients themselves as well as the physicians and nurses caring for the patient, and to examine possible differences in the ratings.68 cancer patients received a pain questionnaire about pain intensity and subjective well-being. At the same time, physicians and nurses answered 7 pain-related questions about each patient.34% of the patients reported strong or very strong pain in the past week, 8% even unbearable pain. 66% felt psychologically distressed, 70% developed anxiety because of pain. 74% believed that pain is an essential part of the disease. Nurses and physicians often underestimate patients' burden of pain. Nevertheless, the rating of the nurses is more accurate than that of the physicians.Physicians and nurses often underestimate pain intensity. It seems that several patients are unable or unwilling to express their pain or that therapists lack adequate methods of pain assessment. To optimize pain treatment, communication between patients, physicians and nurses needs to be improved.

Published
2006

8. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial

Author

Stephan Mose, Karl T. Beer, Michael Henke, Hermann Frommhold, Roland Laszig, Ulrich Burger, Klaus-Dieter Haase, Chris Dougherty, C. Rübe, Ulrich Schäfer, and Burkhard Schilcher

Subjects
medicine.medical_specialty, Darbepoetin alfa, Placebo-controlled study, Comorbidity, Placebo, Gastroenterology, Disease-Free Survival, law.invention, Randomized controlled trial, law, Internal medicine, medicine, Humans, Erythropoietin, Proportional Hazards Models, Epoetin beta, business.industry, Head and neck cancer, Antineoplastic Protocols, Anemia, General Medicine, medicine.disease, Recombinant Proteins, Surgery, Clinical trial, Treatment Outcome, Head and Neck Neoplasms, Carcinoma, Squamous Cell, Radiation Oncology, business, medicine.drug
Abstract

Anaemia is associated with poor cancer control, particularly in patients undergoing radiotherapy. We investigated whether anaemia correction with epoetin beta could improve outcome of curative radiotherapy among patients with head and neck cancer.We did a multicentre, double-blind, randomised, placebo-controlled trial in 351 patients (haemoglobin120 g/L in women or130 g/L in men) with carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx. Patients received curative radiotherapy at 60 Gy for completely (R0) and histologically incomplete (R1) resected disease, or 70 Gy for macroscopically incompletely resected (R2) advanced disease (T3, T4, or nodal involvement) or for primary definitive treatment. All patients were assigned to subcutaneous placebo (n=171) or epoetin beta 300 IU/kg (n=180) three times weekly, from 10-14 days before and continuing throughout radiotherapy. The primary endpoint was locoregional progression-free survival. We assessed also time to locoregional progression and survival. Analysis was by intention to treat.148 (82%) patients given epoetin beta achieved haemoglobin concentrations higher than 140 g/L (women) or 150 g/L (men) compared with 26 (15%) given placebo. However, locoregional progression-free survival was poorer with epoetin beta than with placebo (adjusted relative risk 1.62 [95% CI 1.22-2.14]; p=0.0008). For locoregional progression the relative risk was 1.69 (1.16-2.47, p=0.007) and for survival was 1.39 (1.05-1.84, p=0.02).Epoetin beta corrects anaemia but does not improve cancer control or survival. Disease control might even be impaired. Patients receiving curative cancer treatment and given erythropoietin should be studied in carefully controlled trials.

Published
2003

9. Kombination von Radiotherapie und Gemcitabine

Author

Luther W. Brady, A.N. Rahn, Heinz-D. Böttcher, Stephan Mose, Reiner Class, Hans Weber, and Ági Oszvald

Subjects
Gynecology, medicine.medical_specialty, Combined treatment, Oncology, business.industry, Medicine, Radiology, Nuclear Medicine and imaging, business
Abstract

Das Nukleosidanalogon Gemcitabine weist im Experiment radiotherapieverstarkende Eigenschaften auf. Die vorliegende Ubersichtsarbeit versucht, nach Darstellung der pharmakologischen Daten zur alleinigen Applikation und der klinischen Studien zur kombinierten Anwendung unter Berucksichtigung der zell- und tierexperimentellen Resultate Ruckschlusse fur die klinische Anwendung zu ziehen und Anhaltspunkte fur eine Optimierung der Therapie zu suchen. Material und Methode: Die zur Verfugung stehende Literatur zum Metabolismus und Wirkungsmechanismus von Gemcitabine, zur Evaluierung moglicher Applikationsschemata und zur kombinierten Radiochemotherapie mit Gemcitabine diente der zusammenfassenden Ubersicht. Des Weiteren nutzten wir die zell- und tierexperimentellen Publikationen sowie die Daten aus eigenen Untersuchungen. Ergebnisse: Die guten Tumoransprechraten in klinischen Studien werden von einer hohen Inzidenz von Grad-III/IV-Toxizitaten begleitet, wobei die maximal tolerable Gemcitabine-Dosis (MTD) der verwendeten Schemata immer niedriger als die MTD bei alleiniger Applikation liegt. Die experimentellen Untersuchungen, die sich in vitro bzw. im Tiermodell mit der Deskription und der Klarung des radiotherapieverstarkenden Effekts (insbesondere Zellzyklusbeeinflussung, Depletion des dATP-Pools, Apoptoseinduktion, Inhibition der DNA-Synthese, Reduktion der DNA-Reparatur) befassen, beobachten diesen Effekt konzentrations- und expositionszeitabhangig bereits bei nicht bzw. moderat toxischen Konzentrationen und – unabhangig vom Fraktionierungseffekt der Strahlentherapie – maximal bis zu 72 Stunden nach Exposition. Die Daten lassen darauf schliesen, dass unter notwendiger Beachtung der Einzeldosis und der Zielvolumengrose die prolongierte Infusion bzw. die zweimal wochentlichen, niedrig dosierten Gemcitabine-Applikationen simultan zur Bestrahlung am ehesten die experimentellen Grundlagen berucksichtigen. Schlussfolgerungen: Zweifelsfrei sind die am Patienten gewonnenen Daten fur die Evaluierung eines optimal aufeinander abgestuften Schemas zur Radiochemotherapie mit Gemcitabine von hochster Relevanz. Aber auch wenn es oftmals schwierig ist, experimentelle Daten auf die klinische Situation zu ubertragen, ermoglichen sie es dennoch, ein verbessertes Therapiedesign zu entwerfen, das auf den rationalen Erkenntnissen der Tumorbiologie beruht.

Published
2002

10. Influence of irradiation on therapy-associated psychological distress in breast carcinoma patients

Author

Stephan Mose, K. Budischewski, S.B. Bormeth, A.N. Rahn, Heinz D. Böttcher, and Anja C. Zander-Heinz

Subjects
Adult, Cancer Research, medicine.medical_specialty, Coping (psychology), medicine.medical_treatment, Breast Neoplasms, Structural equation modeling, Breast cancer, Internal medicine, Adaptation, Psychological, medicine, Humans, Radiology, Nuclear Medicine and imaging, Aged, Aged, 80 and over, Gynecology, Radiation, Radiotherapy, business.industry, Cancer, Middle Aged, medicine.disease, Radiation therapy, Distress, Oncology, Anxiety, Female, medicine.symptom, business, Breast carcinoma, Stress, Psychological
Abstract

Purpose: To confirm our assumptions regarding factors that apparently cause psychological distress related to adjuvant radiotherapy in breast cancer patients and to evaluate variables that can predict therapy-associated distress. Methods and Materials: Between January 1997 and April 1998, 111 women (33–84 years) with early-stage breast cancer were irradiated (56 Gy) after breast-conserving surgery. Patients were given self-assessment questionnaires on the first and last day of radiotherapy. Statistical analysis was performed using the structural equation model LISREL, variance analysis, and regression analysis. Results: The internal subject–related factors (coping, radiation-related anxiety, physical distress, psychological distress) reciprocally influenced each other, whereas external radiotherapy-specific factors (environmental influence, confidence in the medical staff) were causally related to coping, anxiety, and distress. Fifty-three percent of the women felt distressed because cancer affected the breast; 48% were initially afraid of radiotherapy. For 36%, anxiety was not reduced during treatment. Highly distressed women were identified by the following parameters: ≤58 years; initial anxiety; they were affected by having breast cancer, were negatively affected by environmental factors, and did not find distraction helpful. Conclusion: Despite considerable individual variability in breast cancer patients, it seems possible to identify women who run a high risk of therapy-associated distress. In these patients, psychosocial support is necessary to reduce treatment-related anxiety and to stabilize confidence in the medical staff.

Published
2001

11. Palliative Radiochemotherapie mit Bendamustin bei fortgeschrittenen Tumorrezidiven im HNO-Bereich

Author

S.B. Bormeth, A.N. Rahn, R. Burkhart Schilcher, Heinz D. Böttcher, Irenäus A. Adamietz, and Stephan Mose

Subjects
Gynecology, Bendamustine, medicine.medical_specialty, Palliative treatment, business.industry, Advanced stage, Bendamustin, Combined treatment, Oncology, Epidermoid carcinoma, medicine, Radiology, Nuclear Medicine and imaging, Head and neck, business, medicine.drug
Abstract

Bei Tumorrezidiven im HNO-Bereich sind die therapeutischen Moglichkeiten durch intensive Vortherapie und durch den Allgemeinzustand der Patienten eingeschrankt. In der palliativen Situation erfordern schmerztherapeutische, kosmetische und pflegerische Probleme eine Behandlung, die bei der limitierten Gesamtprognose dem betroffenen Patienten im Hinblick auf Benefit, Behandlungsdauer und Nebenwirkungsprofil gerecht werden muss. Uberpruft werden sollte die Wirksamkeit und Durchfuhrbarkeit eines palliativen Radiochemotherapiekonzepts. Patienten und Methodik: Behandelt wurden 14 Patienten mit Plattenepitheltumorrezidiven im Kopf-Hals-Bereich (13 Manner, eine Frau). Das mittlere Alter lag bei 56,1 Jahren (Altersspanne 42–76 Jahre). Vortherapie: Radiatio n = 14 (42–71,3 Gy), Operation n = 10, Chemotherapie n = 13. Behandelt wurde mit 100–150 mg Bendamustin pro m2 Korperoberflache (Tag 1 und 2) sowie 15 Gy Radiation (3 Gy/d, Tag 1–5). Erfasst wurden Nebenwirkungen, Remissionsstatus und -dauer, Symptomkontrolle und Uberlebenszeit. Ergebnis: Ansprechen: komplette Remission n = 4, partielle Remission n = 10, deutliche Besserung von 70% der Tumorsymptome. Die Zeit bis zum erneuten Progress betrug 2–104 Wochen. Aufgetretene Nebenwirkungen: Toxizitat CTC-Grad 3 und 4 bei zwei Patienten (14%). Schlussfolgerung: Das vorgestellt Therapieschema ermoglicht auch bei intensiv vorbehandelten Patienten mit fortgeschrittenen inkurablen Tumorrezidiven eine wirkungsvolle palliative Intervention. Das Nebenwirkungsprofil ist gunstig und erlaubt auch eine Behandlung von Patienten mit reduziertem Allgemeinzustand.

Published
2001

12. Wertigkeit der Radiotherapie in der Behandlung des multiplen Myeloms

Author

Heinz D. Böttcher, Corinna E.E. Nierhoff, Stephan Mose, Dagmar Pfitzner, A.N. Rahn, and Mirco Schiemann

Subjects
Gynecology, medicine.medical_specialty, Oncology, Palliative treatment, business.industry, medicine, Radiology, Nuclear Medicine and imaging, business
Abstract

Die chemotherapeutisch ausgerichtete Behandlung des multiplen Myeloms ist bei fehlender kurativer Option durch Masnahmen zur Symptomlinderung und Komplikationsverhinderung gepragt. Die Radiotherapie nimmt im Rahmen der Schmerztherapie, der Behandlung von (drohenden) Frakturen und von Myelonkompressionen eine wichtige Rolle im palliativen Konzept ein. Ziel der vorliegenden retrospektiven Arbeit ist es, anhand dieser Indikationen den Effekt der Strahlentherapie auf Analgesie, Rekalzifizierung und neurologische Symptomatik am eigenen Patientenkollektiv aufzuzeigen und mogliche Einflussfaktoren auf den Therapieeffekt zu evaluieren.

Published
2000

14. VerstÄrkung der radiotherapeutischen wirkung auf HeLa-Zellen durch gemcitabine

Author

Lotte Jüling-Pohlit, U. Ramm, Stephan Mose, Brigitte Taborski, M. Damrau, A.N. Rahn, Martin Karapetian, and Heinz D. Böttcher

Subjects
Radiosensitizer, Pathology, medicine.medical_specialty, business.industry, Molecular biology, Gemcitabine, Squamous carcinoma, On cells, Oncology, Epidermoid carcinoma, In vivo, Colon carcinoma cell, Medicine, Radiology, Nuclear Medicine and imaging, business, Cell survival, medicine.drug
Abstract

Das difluorierte Deoxycytidinderivat Gemcitabine (dFdC) ist ein neues Nukleosidanalogon, das in vivo und in vitro bei soliden Tumoren zytotoxisch wirkt. In Untersuchungen mit Pankreas- und Kolonkarzinomzellinien wurde ein radiosensibilisierender Effekt von dFdC beschrieben. Ziel unserer Untersuchung war die uberprufung dieses Effekts an Plattenepithelkarzinomzellen der Zervix (HeLa-Zellen, ATCC CCL-2). Unter standardisierten Bedingungen wurden HeLa-Zellen in Monolayer-Kulturen mit dFdC in unterschiedlicher Konzentration (0,003, 0,01 und 0,03 umol/1) und Expositionszeit (vier bis 24 Stunden) inkubiert. Die nachfolgende Bestrahlung erfolgte mit 2 bis 6 Gy unmittelbar bzw. zwolf Stunden nach durchgefuhrter Gemcitabine-Exposition. Das Zelluberleben wurde im Koloniebildungstest evaluiert. Die Zeiluberlebenskurven wurden nach Korrektur der chemotherapeutischen ZytotoxizitAt unter Anwendung des linearquadratischen Modells erstellt, um die mittlere Inaktivierungsdosis (MID) berechnen zu konnen. Eine RadiotherapieverstArkung war definiert als VerhAltnis MIDRT(=Kontrolle)/MIDRT+dFdc > 1. Nach vier-bzw. achtstundiger Gemcitabine-Exposition und unmittelbar nachfolgender Bestrahlung errechnet sich bei einer dFdC-Dosis von 0,01 und 0,03 Μmol/l eine VerstArkung der radiotherapeutischen Wirkung um den Faktor 1,07 und 1,14 bzw. 1,04 und 1,22. Bei einer 16-bzw. 24stundigen dFdC-Exposition zeigt sich eine weitere Steigerung des Bestrahlungseffekts bereits fur dFdC-Konzentrationen von > - 0,003 bis 0,03 umol/1 (Faktor 1,08 bis 2,0 bzw. 1,08 bis 2,48). Wird erst zwolf Stunden nach einer 24stundigen dFdC-Exposition (0,01 bzw. 0,03 umol/1) bestrahlt, betrAgt der VerstArkungsfaktor 1,18 bzw. 1,7. Die In-vitro-Untersuchungen an HeLa-Zellen weisen dFdC als potenten Radiosensitizer aus. Die Wirkung der auf die Gemcitabine-Exposition nachfolgenden Radiotherapie wird durch die nicht bzw. kaum zytotoxischen dFdC-Konzentrationen dosis- und zeitabhAngig verstArkt. Gemcitabine (21).21-difluorodeoxycytidine; dFdC) is a new nucleoside analog with promising activity in different solid tumors in vivo and in vitro. As published up to now, combined with irradiation dFdC demonstrates a radio-sensitizing effect on pancreas and colon carcinoma cell lines. We investigated the influence of dFdC on the radiosensitization of human squamous carcinoma cells of the cervix (HeLa-cells, ATCC CCL-2). Under standardized conditions monolayer cultures of HeLa-cells were incubated in medium with dFdC for different times (4 to 24 hours) and exposed to different concentrations (0.003, 0.01 and 0.03 umol/1). Irradiation (2 to 6 Gy, electron beam) followed immediately or 12 hours after dFdC-exposure. Cell survival was determined by colony forming assay. Using the linear-quadratic model cell survival curves were fit after correction for drug-induced cytotoxicity and the mean inactivation dose (MID) was calculated. Radiation enhancement was defined as the ratio MIDRT(=Control)/MIDRT+dFdC > 1. Exposed to gemcitabine for 4 and 8 hours and followed by immediate irradiation the radiation enhancement ratio (Table 1) is 1.07 to 1.14 and 1.04 to 1.22, respectively, if dFdC concentration is > 0.01 to 0.03 umol/1. Further increase of the irradiation effect is demonstrated in cells exposed to > 0.003 to 0.03 imol/l dFdC for 16 and 24 hours (radiation enhancement ratio 1.08 to 2.0 and 1.08 to 2.48, respectively) (Figure 3). If irradiation is applied 12 hours after 24-hour-exposure (0.01 and 0.03 umol/1) the enhancement ratio was 1.18 and 1.7, respectively (Figure 4). In cell cultures the assays combining irradiation with dFdC demonstrate that dFdC is a potent radiation sensitizer of HeLa-cells. The effect of irradiation on cells pre-treated with non- and hardly cytotoxic concentrations of dFdC is increased in dependence of dose and time of exposure.

Published
1999

15. Stellenwert der18F-Fluordeoxyglucose-Positronen-emissionstomographie in der Radiotherapieplanung von Kopf-Hals-Tumoren

Author

Heinz D. Böttcher, Sonali Sengupta, A.N. Rahn, Stephan Mose, Stefan Adams, Richard P. Baum, S.B. Bormeth, Gustav Hör, and Irenäus A. Adamietz

Subjects
Lymphatic metastasis, Head neck tumors, medicine.diagnostic_test, business.industry, medicine.medical_treatment, Fluorodeoxyglucose positron emission tomography, Radiation therapy, Oncology, Local radiotherapy, Positron emission tomography, medicine, Radiology, Nuclear Medicine and imaging, Neoplasm staging, Nuclear medicine, business, Head and neck
Abstract

Hintergrund Eine exakte Ausbreitungsdiagnostik ist Voraussetzung fur die individualisierte Bestrahlungsplanung bei Patienten mit Kopf-Hals-Tumoren. Trotz hoher Zuverlassigkeit der in der Routine eingesetzten Verfahren Computer-und Kernspintomographie ist die sichere Diagnostik eines lymphonodalen Tumorbefalls oft nicht moglich. Wir untersuchten im Rahmen einer Studie, ob die zusatzliche Durchfuhrung einer18F-Fluordeoxyglucose-Positronenemissionstomographie (FDG-PET) hier einen fur die Radiotherapieplanung relevanten Informationsgewinn erbringt.

Published
1998

16. Verbesserte Reproduzierbarkeit und erhöhter Komfort durch standardisierte Lagerungshilfe bei der Bestrahlung der weiblichen Brust

Author

Heinz-Dietrich Böttcher, Stephan Mose, A Kostka, F. Saran, C. Thilmann, and I.A. Adamietz

Subjects
Gynecology, medicine.medical_specialty, Reproducibility, Oncology, business.industry, medicine, Radiology, Nuclear Medicine and imaging, Biomedical equipment, business, Surgery
Abstract

Hintergrund Lagerungs-und Fixationstechniken sind Voraussetzung fur eine prazise Radiotherapie. Die angebotenen standardisierten Lagerungshilfen sind unzureichend. Daher wurde von uns eine neue, allgemein anwendbare Lagerungshilfe aus Hartschaumstoff zur Mammabestrahlung entworfen und in einer prospektiven Studie auf klinische Eignung gepruft.

Published
1998

17. Complement and endothelial cell activation in COVID-19 patients compared to controls with suspected SARS-CoV-2 infection: A prospective cohort study

Author

Flavio Bruni, Panteleimon Charitos, Maurin Lampart, Stephan Moser, Martin Siegemund, Roland Bingisser, Stefan Osswald, Stefano Bassetti, Raphael Twerenbold, Marten Trendelenburg, Katharina M. Rentsch, and Michael Osthoff

Subjects
COVID-19, complement system, endothelial cells, SARS-CoV-2, ICAM-1, VCAM-1, Immunologic diseases. Allergy, RC581-607
Abstract

BackgroundThromboinflammation may influence disease outcome in COVID-19. We aimed to evaluate complement and endothelial cell activation in patients with confirmed COVID-19 compared to controls with clinically suspected but excluded SARS-CoV-2 infection.MethodsIn a prospective, observational, single-center study, patients presenting with clinically suspected COVID-19 were recruited in the emergency department. Blood samples on presentation were obtained for analysis of C5a, sC5b-9, E-selectin, Galectin-3, ICAM-1 and VCAM-1.Results153 cases and 166 controls (suffering mainly from non-SARS-CoV-2 respiratory viral infections, non-infectious inflammatory conditions and bacterial pneumonia) were included. Hospital admission occurred in 62% and 45% of cases and controls, respectively. C5a and VCAM-1 concentrations were significantly elevated and E-selectin concentrations decreased in COVID-19 out- and inpatients compared to the respective controls. However, relative differences in outpatients vs. inpatients in most biomarkers were comparable between cases and controls. Elevated concentrations of C5a, Galectin-3, ICAM-1 and VCAM-1 on presentation were associated with the composite outcome of ICU- admission or 30-day mortality in COVID-19 and controls, yet more pronounced in COVID-19. C5a and sC5b-9 concentrations were significantly higher in COVID-19 males vs. females, which was not observed in the control group.ConclusionsOur data indicate an activation of the complement cascade and endothelium in COVID-19 beyond a nonspecific inflammatory trigger as observed in controls (i.e., “over”-activation).

Published
2022
Full Text
View/download PDF

18. Welche Faktoren beeinflussen die Reproduzierbarkeit der Patientenlagerung in der täglichen Bestrahlungsroutine?

Author

F. Saran, I.A. Adamietz, C. Thilmann, A. Buchner, Heinz-Dietrich Böttcher, and Stephan Mose

Subjects
Gynecology, medicine.medical_specialty, Cobalt Radioisotopes, Palliative care, Oncology, business.industry, medicine, Patient positioning, Radiology, Nuclear Medicine and imaging, business
Abstract

Uber Faktoren, die in der taglichen Bestrahlungsroutine die Reproduzierbarkeit der Patientenpositionierung beeinflussen konnen, ist nur wenig bekannt. Ziel war es, in einer prospektiven Erhebung Faktoren zu bestimmen, die das Auftreten von Feldfehleinstellungen bei freier Lagerung begunstigen, und deren klinische Relevanz zu beurteilen. 53 Patienten wurden perkutan mit Kobalt 60 ohne Fixationshilfen bestrahlt. In wochentlichen Abstanden wurden von allen Bestrahlungsfeldern Verifikationsaufnahmen angefertigt. Neben der Erhebung von Basisdaten (Alter, Grose, Gewicht, Allgemeinzustand, Bestrahlungsindikation) wurden die Patienten ebenfalls in wochentlichen Abstanden bezuglich ihrer Empfindungen (Schmerzen, Angst, Unruhe) wahrend der Bestrahlung befragt und die aktuelle Arbeitsbelastung des Personals ermittelt. Aus der Lage abgebildeter anatomischer Strukturen bezuglich der Feldgrenzen wurden die Abweichungen der Verifikations-zu den Simulationsaufnahmen bestimmt. Die Patientendaten wurden mit der Zahl der Feldfehleinstellungen (Abweichungen von mehr als 1 cm) korreliert. Gehauft fehleingestellt waren: Patienten in reduziertem Allgemeinzustand, palliativ bestrahlte Patienten, Patienten mit Schmerzen, Angst, Unruhe wahrend der Simulation bzw. der Bestrahlung und Patienten mit einem Gewicht von mehr als 90 kg. Die Zahl der Feldfehleinstellungen wuchs signifikant mit der Arbeitsbelastung des medizinisch-technischen Personals. Von besonderer klinischer Relevanz ist die Problematik der Reproduzierbarkeit der freien Lagerung bei der palliativen Strablenbehandlung. Suffiziente Schmerzeinstellung und schmerzfreie. bequeme Lagerung vermindern hier die Zahl der Feldfehleinstellungen. Bei der kurativen Bestrahlung sollten verstarkt Fixationstechniken zur Anwendung kommen.

Published
1997

19. Myelodysplastic Syndrome (MDS)

Author

Nisha R. Patel, Michael L. Wong, Anthony E. Dragun, Stephan Mose, Bernadine R. Donahue, Jay S. Cooper, Filip T. Troicki, Darek Michalski, M. Saiful Huq, Ramesh Rengan, Charles R. Thomas, Jay E. Reiff, Erik Limbergen, Lydia T. Komarnicky-Kocher, Fiori Alite, Brandon J. Fisher, Yan Yu, Laura Doyle, Lindsay G. Jensen, Brent S. Rose, Arno J. Mundt, Bradley J. Huth, Christin A. Knowlton, Michelle Kolton Mackay, George E. Laramore, Jay J. Liao, Jason K. Rockhill, David E. Wazer, John W. Wong, Hedvig Hricak, Oguz Akin, Hebert Alberto Vargas, Bruce G. Haffty, Claudia E. Rübe, Timothy Holmes, Charlie Ma, Lu Wang, Rene Rubin, Gerhard G. Grabenbauer, Loren K. Mell, Jaganmohan Poli, Theodore E. Yaeger, Christian Weiss, Claus Roedel, Caspian Oliai, Curt Heese, and James H. Brashears

Published
2013

20. Brachytherapy-GyN

Author

Stephan Mose, Brandon J. Fisher, Iris Rusu, Charlie Ma, Lu Wang, Larry C. Daugherty, Tod W. Speer, Anthony E. Dragun, Rene Rubin, Claudia Rübe, James H. Brashears, Christian Weiss, Claus Roedel, Edward J. Gracely, Lindsay G. Jensen, Brent S. Rose, Loren K. Mell, Arno J. Mundt, Albert S. DeNittis, Christin A. Knowlton, Michelle Kolton Mackay, Yan Yu, Laura Doyle, Cheng B. Saw, Ning J. Yue, Nisha R. Patel, Michael L. Wong, Brian F. Hasson, Daniel Yeung, Jatinder Palta, David E. Wazer, Susan M. Varnum, Marianne B. Sowa, and William F. Morgan

Published
2013

21. Leukemia in General

Author

Patrizia Guerrieri, Paolo Montemaggi, Volker Budach, Carmen Stromberger, Anthony E. Dragun, Filip T. Troicki, Jaganmohan Poli, James H. Brashears, George E. Laramore, Jay J. Liao, Jason K. Rockhill, Carlos A. Perez, Wade L. Thorstad, Caspian Oliai, Tony S. Quang, Linna Li, John P. Lamond, Stephan Mose, Timothy C. Zhu, Ken K.-H. Wang, Tod W. Speer, Rachelle Lanciano, David E. Wazer, Ning J. Yue, Erik Limbergen, Cheng B. Saw, Brandon J. Fisher, Larry C. Daugherty, Jingbo Wang, Feng-Ming Kong, and Iris Rusu

Published
2013

22. CAMPEP

Author

Christin A. Knowlton, Michelle Kolton Mackay, Tod W. Speer, Robyn B. Vera, Douglas W. Arthur, David E. Wazer, Rachelle Lanciano, James H. Brashears, Filip T. Troicki, Jaganmohan Poli, Theodore E. Yaeger, Stephan Mose, Anthony E. Dragun, Ramesh Rengan, Charles R. Thomas, Bernadine R. Donahue, Jay S. Cooper, Patrizia Guerrieri, Paolo Montemaggi, Carsten Nieder, John P. Christodouleas, Caspian Oliai, Curt Heese, Carlos A. Perez, Wade L. Thorstad, Darek Michalski, M. Saiful Huq, Brandon J. Fisher, Erik Limbergen, Bok Ai Choo, Jiade J. Lu, Luther W. Brady, Larry C. Daugherty, Claudia Rübe, Daniel Yeung, Jatinder Palta, Bradley J. Huth, Claudia E. Rübe, Jay E. Reiff, Volker Budach, Edward J. Gracely, Timothy Holmes, Daniel J. Scanderbeg, Johannes Classen, George E. Laramore, Jay J. Liao, and Jason K. Rockhill

Published
2013

23. Binding Site Barrier

Author

Stephan Mose, Brandon J. Fisher, Iris Rusu, Charlie Ma, Lu Wang, Larry C. Daugherty, Tod W. Speer, Anthony E. Dragun, Rene Rubin, Claudia Rübe, James H. Brashears, Christian Weiss, Claus Roedel, Edward J. Gracely, Lindsay G. Jensen, Brent S. Rose, Loren K. Mell, Arno J. Mundt, Albert S. DeNittis, Christin A. Knowlton, Michelle Kolton Mackay, Yan Yu, Laura Doyle, Cheng B. Saw, Ning J. Yue, Nisha R. Patel, Michael L. Wong, Brian F. Hasson, Daniel Yeung, Jatinder Palta, David E. Wazer, Susan M. Varnum, Marianne B. Sowa, and William F. Morgan

Published
2013

24. Small Cell Lung Cancer

Author

Lindsay G. Jensen, Loren K. Mell, Christin A. Knowlton, Michelle Kolton Mackay, Filip T. Troicki, Jaganmohan Poli, Edward J. Gracely, Carlos A. Perez, Wade L. Thorstad, Stephan Mose, Christian Weiss, Claus Roedel, Johannes Classen, Lydia T. Komarnicky-Kocher, James H. Brashears, Curt Heese, Brandon J. Fisher, Larry C. Daugherty, John P. Christodouleas, Robert D. Forrest, Christopher G. Ainsley, Zelig Tochner, Stephen M. Hahn, Eli Glatstein, Bradley J. Huth, Rene Rubin, John W. Wong, David E. Wazer, Volker Budach, Hedvig Hricak, Oguz Akin, Hebert Alberto Vargas, Claudia E. Rübe, Anthony E. Dragun, Daniel J. Indelicato, Robert H. Sagerman, Caspian Oliai, John P. Lamond, Patrizia Guerrieri, Paolo Montemaggi, Brian F. Hasson, Tony S. Quang, Linna Li, Daniel Yeung, Jatinder Palta, Erik Limbergen, Mary Ellen Masterson-McGary, Feng-Ming Kong, Jingbo Wang, and Jay E. Reiff

Published
2013

25. Centigray (cGy)

Author

Christin A. Knowlton, Michelle Kolton Mackay, Tod W. Speer, Robyn B. Vera, Douglas W. Arthur, David E. Wazer, Rachelle Lanciano, James H. Brashears, Filip T. Troicki, Jaganmohan Poli, Theodore E. Yaeger, Stephan Mose, Anthony E. Dragun, Ramesh Rengan, Charles R. Thomas, Bernadine R. Donahue, Jay S. Cooper, Patrizia Guerrieri, Paolo Montemaggi, Carsten Nieder, John P. Christodouleas, Caspian Oliai, Curt Heese, Carlos A. Perez, Wade L. Thorstad, Darek Michalski, M. Saiful Huq, Brandon J. Fisher, Erik Limbergen, Bok Ai Choo, Jiade J. Lu, Luther W. Brady, Larry C. Daugherty, Claudia Rübe, Daniel Yeung, Jatinder Palta, Bradley J. Huth, Claudia E. Rübe, Jay E. Reiff, Volker Budach, Edward J. Gracely, Timothy Holmes, Daniel J. Scanderbeg, Johannes Classen, George E. Laramore, Jay J. Liao, and Jason K. Rockhill

Published
2013

26. Statistically Significant

Author

Lindsay G. Jensen, Loren K. Mell, Christin A. Knowlton, Michelle Kolton Mackay, Filip T. Troicki, Jaganmohan Poli, Edward J. Gracely, Carlos A. Perez, Wade L. Thorstad, Stephan Mose, Christian Weiss, Claus Roedel, Johannes Classen, Lydia T. Komarnicky-Kocher, James H. Brashears, Curt Heese, Brandon J. Fisher, Larry C. Daugherty, John P. Christodouleas, Robert D. Forrest, Christopher G. Ainsley, Zelig Tochner, Stephen M. Hahn, Eli Glatstein, Bradley J. Huth, Rene Rubin, John W. Wong, David E. Wazer, Volker Budach, Hedvig Hricak, Oguz Akin, Hebert Alberto Vargas, Claudia E. Rübe, Anthony E. Dragun, Daniel J. Indelicato, Robert H. Sagerman, Caspian Oliai, John P. Lamond, Patrizia Guerrieri, Paolo Montemaggi, Brian F. Hasson, Tony S. Quang, Linna Li, Daniel Yeung, Jatinder Palta, Erik Limbergen, Mary Ellen Masterson-McGary, Feng-Ming Kong, Jingbo Wang, and Jay E. Reiff

Published
2013

27. Ethmoid Sinus

Author

Anthony E. Dragun, Paul J. Schilling, Tod W. Speer, Feng-Ming Kong, Jingbo Wang, Hedvig Hricak, Oguz Akin, Alberto Vargas, Paula R. Salanitro, John W. Wong, Erik Limbergen, Christin A. Knowlton, Michelle Kolton Mackay, Filip T. Troicki, Jaganmohan Poli, Claudia E. Rübe, James H. Brashears, Susan M. Varnum, Marianne B. Sowa, William F. Morgan, Rene Rubin, Brandon J. Fisher, Larry C. Daugherty, Charlie Ma, Lu Wang, Daniel J. Indelicato, Robert H. Sagerman, Curt Heese, Stephan Mose, Lindsay G. Jensen, Brent S. Rose, Arno J. Mundt, Albert S. DeNittis, Carlos A. Perez, Wade L. Thorstad, Cheng B. Saw, Theodore E. Yaeger, Jo Ann Chalal, Jorge E. Freire, Carol L. Shields, Jerry A. Shields, Luther W. Brady, and Jay E. Reiff

Published
2013

28. Class I Hysterectomy

Author

Christin A. Knowlton, Michelle Kolton Mackay, Tod W. Speer, Robyn B. Vera, Douglas W. Arthur, David E. Wazer, Rachelle Lanciano, James H. Brashears, Filip T. Troicki, Jaganmohan Poli, Theodore E. Yaeger, Stephan Mose, Anthony E. Dragun, Ramesh Rengan, Charles R. Thomas, Bernadine R. Donahue, Jay S. Cooper, Patrizia Guerrieri, Paolo Montemaggi, Carsten Nieder, John P. Christodouleas, Caspian Oliai, Curt Heese, Carlos A. Perez, Wade L. Thorstad, Darek Michalski, M. Saiful Huq, Brandon J. Fisher, Erik Limbergen, Bok Ai Choo, Jiade J. Lu, Luther W. Brady, Larry C. Daugherty, Claudia Rübe, Daniel Yeung, Jatinder Palta, Bradley J. Huth, Claudia E. Rübe, Jay E. Reiff, Volker Budach, Edward J. Gracely, Timothy Holmes, Daniel J. Scanderbeg, Johannes Classen, George E. Laramore, Jay J. Liao, and Jason K. Rockhill

Published
2013

29. Pain Management Specialist

Author

Larry C. Daugherty, Brandon J. Fisher, Christin A. Knowlton, Michelle Kolton Mackay, David E. Wazer, Anthony E. Dragun, James H. Brashears, Lydia T. Komarnicky-Kocher, Fiori Alite, Feng-Ming Kong, Jingbo Wang, Filip T. Troicki, Jaganmohan Poli, Rene Rubin, Daniel Yeung, Jatinder Palta, Charlie Ma, Lu Wang, Stephan Mose, Felipe A. Calvo, Hedvig Hricak, Oguz Akin, Hebert Alberto Vargas, Daniel J. Indelicato, Robert H. Sagerman, Erik Limbergen, Yan Yu, Laura Doyle, Darek Michalski, M. Saiful Huq, Theodore E. Yaeger, Cheri Yaeger, Jay E. Reiff, Jo Ann Chalal, Lindsay G. Jensen, Loren K. Mell, Ramesh Rengan, Charles R. Thomas, Edward J. Gracely, John P. Christodouleas, Claudia E. Rübe, Paul J. Schilling, Tony S. Quang, Ari D. Brooks, T. Wiegel, D. Bottke, A. Ghazal, M. Schrader, Bradley J. Huth, and Curt Heese

Published
2013

30. Perioperative Brachytherapy

Author

Larry C. Daugherty, Brandon J. Fisher, Christin A. Knowlton, Michelle Kolton Mackay, David E. Wazer, Anthony E. Dragun, James H. Brashears, Lydia T. Komarnicky-Kocher, Fiori Alite, Feng-Ming Kong, Jingbo Wang, Filip T. Troicki, Jaganmohan Poli, Rene Rubin, Daniel Yeung, Jatinder Palta, Charlie Ma, Lu Wang, Stephan Mose, Felipe A. Calvo, Hedvig Hricak, Oguz Akin, Hebert Alberto Vargas, Daniel J. Indelicato, Robert H. Sagerman, Erik Limbergen, Yan Yu, Laura Doyle, Darek Michalski, M. Saiful Huq, Theodore E. Yaeger, Cheri Yaeger, Jay E. Reiff, Jo Ann Chalal, Lindsay G. Jensen, Loren K. Mell, Ramesh Rengan, Charles R. Thomas, Edward J. Gracely, John P. Christodouleas, Claudia E. Rübe, Paul J. Schilling, Tony S. Quang, Ari D. Brooks, T. Wiegel, D. Bottke, A. Ghazal, M. Schrader, Bradley J. Huth, and Curt Heese

Published
2013

31. Mycosis Fungoides

Author

Nisha R. Patel, Michael L. Wong, Anthony E. Dragun, Stephan Mose, Bernadine R. Donahue, Jay S. Cooper, Filip T. Troicki, Darek Michalski, M. Saiful Huq, Ramesh Rengan, Charles R. Thomas, Jay E. Reiff, Erik Limbergen, Lydia T. Komarnicky-Kocher, Fiori Alite, Brandon J. Fisher, Yan Yu, Laura Doyle, Lindsay G. Jensen, Brent S. Rose, Arno J. Mundt, Bradley J. Huth, Christin A. Knowlton, Michelle Kolton Mackay, George E. Laramore, Jay J. Liao, Jason K. Rockhill, David E. Wazer, John W. Wong, Hedvig Hricak, Oguz Akin, Hebert Alberto Vargas, Bruce G. Haffty, Claudia E. Rübe, Timothy Holmes, Charlie Ma, Lu Wang, Rene Rubin, Gerhard G. Grabenbauer, Loren K. Mell, Jaganmohan Poli, Theodore E. Yaeger, Christian Weiss, Claus Roedel, Caspian Oliai, Curt Heese, and James H. Brashears

Published
2013

32. Human Papilloma Virus (HPV)

Author

Claudia E. Rübe, Bernadine R. Donahue, Jay S. Cooper, Caspian Oliai, Yan Yu, Laura Doyle, Rene Rubin, Darek Michalski, M. Saiful Huq, Filip T. Troicki, Jaganmohan Poli, Carlos A. Perez, Wade L. Thorstad, Lindsay G. Jensen, Brent S. Rose, Arno J. Mundt, Anthony E. Dragun, Stephan Mose, Christin A. Knowlton, Michelle Kolton Mackay, Bradley J. Huth, Claus Roedel, Erik Limbergen, Brandon J. Fisher, Larry C. Daugherty, Tod W. Speer, Hans-Peter Heilmann, Theodore E. Yaeger, Feng-Ming Kong, Jingbo Wang, Patrizia Guerrieri, Paolo Montemaggi, Gerhard G. Grabenbauer, Volker Budach, Carsten Nieder, Talha Shaikh, Jacqueline Emrich, Lydia T. Komarnicky-Kocher, Ramesh Rengan, and Charles R. Thomas

Published
2013

33. Endometrium

Author

Anthony E. Dragun, Paul J. Schilling, Tod W. Speer, Feng-Ming Kong, Jingbo Wang, Hedvig Hricak, Oguz Akin, Alberto Vargas, Paula R. Salanitro, John W. Wong, Erik Limbergen, Christin A. Knowlton, Michelle Kolton Mackay, Filip T. Troicki, Jaganmohan Poli, Claudia E. Rübe, James H. Brashears, Susan M. Varnum, Marianne B. Sowa, William F. Morgan, Rene Rubin, Brandon J. Fisher, Larry C. Daugherty, Charlie Ma, Lu Wang, Daniel J. Indelicato, Robert H. Sagerman, Curt Heese, Stephan Mose, Lindsay G. Jensen, Brent S. Rose, Arno J. Mundt, Albert S. DeNittis, Carlos A. Perez, Wade L. Thorstad, Cheng B. Saw, Theodore E. Yaeger, Jo Ann Chalal, Jorge E. Freire, Carol L. Shields, Jerry A. Shields, Luther W. Brady, and Jay E. Reiff

Published
2013

34. Adrenal Carcinoma

Author

Brian F. Hasson, Charlie Ma, Lu Wang, David E. Wazer, Jay E. Reiff, Brandon J. Fisher, Tod W. Speer, James H. Brashears, John P. Christodouleas, Anthony E. Dragun, Volker Budach, Timothy Holmes, Filip T. Troicki, Jaganmohan Poli, Lindsay G. Jensen, Loren K. Mell, Stephan Mose, Erik Limbergen, Cheng B. Saw, Nisha R. Patel, Michael L. Wong, Ning J. Yue, Curt Heese, Ramesh Rengan, Charles R. Thomas, Rene Rubin, Jo Ann Chalal, Gerhard G. Grabenbauer, Brent S. Rose, Arno J. Mundt, Daniel J. Indelicato, Robert H. Sagerman, Lydia T. Komarnicky-Kocher, Christin A. Knowlton, Michelle Kolton Mackay, Darek Michalski, and M. Saiful Huq

Published
2013

35. Myelopathy

Author

Nisha R. Patel, Michael L. Wong, Anthony E. Dragun, Stephan Mose, Bernadine R. Donahue, Jay S. Cooper, Filip T. Troicki, Darek Michalski, M. Saiful Huq, Ramesh Rengan, Charles R. Thomas, Jay E. Reiff, Erik Limbergen, Lydia T. Komarnicky-Kocher, Fiori Alite, Brandon J. Fisher, Yan Yu, Laura Doyle, Lindsay G. Jensen, Brent S. Rose, Arno J. Mundt, Bradley J. Huth, Christin A. Knowlton, Michelle Kolton Mackay, George E. Laramore, Jay J. Liao, Jason K. Rockhill, David E. Wazer, John W. Wong, Hedvig Hricak, Oguz Akin, Hebert Alberto Vargas, Bruce G. Haffty, Claudia E. Rübe, Timothy Holmes, Charlie Ma, Lu Wang, Rene Rubin, Gerhard G. Grabenbauer, Loren K. Mell, Jaganmohan Poli, Theodore E. Yaeger, Christian Weiss, Claus Roedel, Caspian Oliai, Curt Heese, and James H. Brashears

Published
2013

36. Uniform Scanning (US)

Author

Paul J. Schilling, Daniel Yeung, Jatinder Palta, Carlos A. Perez, Stephan Mose, Michelle Kolton Mackay, and Christin A. Knowlton

Published
2013

37. Malignant Mesothelioma

Author

Nisha R. Patel, Michael L. Wong, Anthony E. Dragun, Stephan Mose, Bernadine R. Donahue, Jay S. Cooper, Filip T. Troicki, Darek Michalski, M. Saiful Huq, Ramesh Rengan, Charles R. Thomas, Jay E. Reiff, Erik Limbergen, Lydia T. Komarnicky-Kocher, Fiori Alite, Brandon J. Fisher, Yan Yu, Laura Doyle, Lindsay G. Jensen, Brent S. Rose, Arno J. Mundt, Bradley J. Huth, Christin A. Knowlton, Michelle Kolton Mackay, George E. Laramore, Jay J. Liao, Jason K. Rockhill, David E. Wazer, John W. Wong, Hedvig Hricak, Oguz Akin, Hebert Alberto Vargas, Bruce G. Haffty, Claudia E. Rübe, Timothy Holmes, Charlie Ma, Lu Wang, Rene Rubin, Gerhard G. Grabenbauer, Loren K. Mell, Jaganmohan Poli, Theodore E. Yaeger, Christian Weiss, Claus Roedel, Caspian Oliai, Curt Heese, and James H. Brashears

Published
2013

38. Myasthenia Gravis

Author

Nisha R. Patel, Michael L. Wong, Anthony E. Dragun, Stephan Mose, Bernadine R. Donahue, Jay S. Cooper, Filip T. Troicki, Darek Michalski, M. Saiful Huq, Ramesh Rengan, Charles R. Thomas, Jay E. Reiff, Erik Limbergen, Lydia T. Komarnicky-Kocher, Fiori Alite, Brandon J. Fisher, Yan Yu, Laura Doyle, Lindsay G. Jensen, Brent S. Rose, Arno J. Mundt, Bradley J. Huth, Christin A. Knowlton, Michelle Kolton Mackay, George E. Laramore, Jay J. Liao, Jason K. Rockhill, David E. Wazer, John W. Wong, Hedvig Hricak, Oguz Akin, Hebert Alberto Vargas, Bruce G. Haffty, Claudia E. Rübe, Timothy Holmes, Charlie Ma, Lu Wang, Rene Rubin, Gerhard G. Grabenbauer, Loren K. Mell, Jaganmohan Poli, Theodore E. Yaeger, Christian Weiss, Claus Roedel, Caspian Oliai, Curt Heese, and James H. Brashears

Published
2013

39. Alkylating Agents

Author

Brian F. Hasson, Charlie Ma, Lu Wang, David E. Wazer, Jay E. Reiff, Brandon J. Fisher, Tod W. Speer, James H. Brashears, John P. Christodouleas, Anthony E. Dragun, Volker Budach, Timothy Holmes, Filip T. Troicki, Jaganmohan Poli, Lindsay G. Jensen, Loren K. Mell, Stephan Mose, Erik Limbergen, Cheng B. Saw, Nisha R. Patel, Michael L. Wong, Ning J. Yue, Curt Heese, Ramesh Rengan, Charles R. Thomas, Rene Rubin, Jo Ann Chalal, Gerhard G. Grabenbauer, Brent S. Rose, Arno J. Mundt, Daniel J. Indelicato, Robert H. Sagerman, Lydia T. Komarnicky-Kocher, Christin A. Knowlton, Michelle Kolton Mackay, Darek Michalski, and M. Saiful Huq

Published
2013

40. Prostate Seed Implants (PSI)

Author

Larry C. Daugherty, Brandon J. Fisher, Christin A. Knowlton, Michelle Kolton Mackay, David E. Wazer, Anthony E. Dragun, James H. Brashears, Lydia T. Komarnicky-Kocher, Fiori Alite, Feng-Ming Kong, Jingbo Wang, Filip T. Troicki, Jaganmohan Poli, Rene Rubin, Daniel Yeung, Jatinder Palta, Charlie Ma, Lu Wang, Stephan Mose, Felipe A. Calvo, Hedvig Hricak, Oguz Akin, Hebert Alberto Vargas, Daniel J. Indelicato, Robert H. Sagerman, Erik Limbergen, Yan Yu, Laura Doyle, Darek Michalski, M. Saiful Huq, Theodore E. Yaeger, Cheri Yaeger, Jay E. Reiff, Jo Ann Chalal, Lindsay G. Jensen, Loren K. Mell, Ramesh Rengan, Charles R. Thomas, Edward J. Gracely, John P. Christodouleas, Claudia E. Rübe, Paul J. Schilling, Tony S. Quang, Ari D. Brooks, T. Wiegel, D. Bottke, A. Ghazal, M. Schrader, Bradley J. Huth, and Curt Heese

Published
2013

41. Urothelial Carcinoma

Author

Paul J. Schilling, Daniel Yeung, Jatinder Palta, Carlos A. Perez, Stephan Mose, Michelle Kolton Mackay, and Christin A. Knowlton

Published
2013

42. Effective Half-Life

Author

Anthony E. Dragun, Paul J. Schilling, Tod W. Speer, Feng-Ming Kong, Jingbo Wang, Hedvig Hricak, Oguz Akin, Alberto Vargas, Paula R. Salanitro, John W. Wong, Erik Limbergen, Christin A. Knowlton, Michelle Kolton Mackay, Filip T. Troicki, Jaganmohan Poli, Claudia E. Rübe, James H. Brashears, Susan M. Varnum, Marianne B. Sowa, William F. Morgan, Rene Rubin, Brandon J. Fisher, Larry C. Daugherty, Charlie Ma, Lu Wang, Daniel J. Indelicato, Robert H. Sagerman, Curt Heese, Stephan Mose, Lindsay G. Jensen, Brent S. Rose, Arno J. Mundt, Albert S. DeNittis, Carlos A. Perez, Wade L. Thorstad, Cheng B. Saw, Theodore E. Yaeger, Jo Ann Chalal, Jorge E. Freire, Carol L. Shields, Jerry A. Shields, Luther W. Brady, and Jay E. Reiff

Published
2013

43. Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC)

Author

Brian F. Hasson, Charlie Ma, Lu Wang, David E. Wazer, Jay E. Reiff, Brandon J. Fisher, Tod W. Speer, James H. Brashears, John P. Christodouleas, Anthony E. Dragun, Volker Budach, Timothy Holmes, Filip T. Troicki, Jaganmohan Poli, Lindsay G. Jensen, Loren K. Mell, Stephan Mose, Erik Limbergen, Cheng B. Saw, Nisha R. Patel, Michael L. Wong, Ning J. Yue, Curt Heese, Ramesh Rengan, Charles R. Thomas, Rene Rubin, Jo Ann Chalal, Gerhard G. Grabenbauer, Brent S. Rose, Arno J. Mundt, Daniel J. Indelicato, Robert H. Sagerman, Lydia T. Komarnicky-Kocher, Christin A. Knowlton, Michelle Kolton Mackay, Darek Michalski, and M. Saiful Huq

Published
2013

44. Reactor Explosions

Author

Ning J. Yue, Kent Lambert, Jay E. Reiff, Anthony E. Dragun, Jean St. Germain, Susan M. Varnum, Marianne B. Sowa, William F. Morgan, Grace J. Kim, James H. Brashears, Lydia T. Komarnicky-Kocher, Claudia Rübe, Christin A. Knowlton, Michelle Kolton Mackay, Hedvig Hricak, Oguz Akin, Hebert Alberto Vargas, Darek Michalski, M. Saiful Huq, Brandon J. Fisher, Filip T. Troicki, Jaganmohan Poli, Mary Ellen Masterson-McGary, Luther W. Brady, Michael L. Wong, Edward J. Gracely, Daniel Yeung, Jatinder Palta, John P. Christodouleas, Yan Yu, Laura Doyle, Timothy Holmes, Claus Rödel, Carsten Nieder, Johannes A. Langendijk, George E. Laramore, Jay J. Liao, Jason K. Rockhill, Erik Limbergen, Stephan Mose, John P. Lamond, Larry C. Daugherty, Robert H. Sagerman, and Caspian Oliai

Published
2013

45. Torus Tubarius

Author

Tod W. Speer, Rene Rubin, Iris Rusu, Yan Yu, Laura Doyle, Cheng B. Saw, Ning J. Yue, Johannes Classen, Carsten Nieder, Feng-Ming Kong, Jingbo Wang, Lindsay G. Jensen, Brent S. Rose, Arno J. Mundt, Ramesh Rengan, Charles R. Thomas, Nisha R. Patel, Michael L. Wong, Brandon J. Fisher, Larry C. Daugherty, Christin A. Knowlton, Michelle Kolton Mackay, Curt Heese, David Lightfoot, Lydia T. Komarnicky-Kocher, Fiori Alite, Christian Weiss, Claus Roedel, Patrizia Guerrieri, Paolo Montemaggi, Loren K. Mell, Stephan Mose, Brian F. Hasson, Darek Michalski, M. Saiful Huq, Claudia E. Rübe, Bradley J. Huth, Tony S. Quang, and Edward J. Gracely

Published
2013

46. Epidermoid Intradermal Carcinoma

Author

Anthony E. Dragun, Paul J. Schilling, Tod W. Speer, Feng-Ming Kong, Jingbo Wang, Hedvig Hricak, Oguz Akin, Alberto Vargas, Paula R. Salanitro, John W. Wong, Erik Limbergen, Christin A. Knowlton, Michelle Kolton Mackay, Filip T. Troicki, Jaganmohan Poli, Claudia E. Rübe, James H. Brashears, Susan M. Varnum, Marianne B. Sowa, William F. Morgan, Rene Rubin, Brandon J. Fisher, Larry C. Daugherty, Charlie Ma, Lu Wang, Daniel J. Indelicato, Robert H. Sagerman, Curt Heese, Stephan Mose, Lindsay G. Jensen, Brent S. Rose, Arno J. Mundt, Albert S. DeNittis, Carlos A. Perez, Wade L. Thorstad, Cheng B. Saw, Theodore E. Yaeger, Jo Ann Chalal, Jorge E. Freire, Carol L. Shields, Jerry A. Shields, Luther W. Brady, and Jay E. Reiff

Published
2013

47. Fecal Occult Blood Test

Author

Patrizia Guerrieri, Paolo Montemaggi, Bradley J. Huth, Claus Roedel, Stephan Mose, Hedvig Hricak, Oguz Akin, Hebert Alberto Vargas, Daniel J. Indelicato, Robert H. Sagerman, Lydia T. Komarnicky-Kocher, Anthony E. Dragun, Brandon J. Fisher, Larry C. Daugherty, Darek Michalski, M. Saiful Huq, Brian F. Hasson, Lindsay G. Jensen, Loren K. Mell, and Filip T. Troicki

Published
2013

48. Vinca Alkaloids

Author

Patrizia Guerrieri, Paolo Montemaggi, Rene Rubin, Erik Limbergen, Filip T. Troicki, Jaganmohan Poli, James H. Brashears, Tony S. Quang, Stephan Mose, Darek Michalski, and M. Saiful Huq

Published
2013

49. Type I Error

Author

Tod W. Speer, Rene Rubin, Iris Rusu, Yan Yu, Laura Doyle, Cheng B. Saw, Ning J. Yue, Johannes Classen, Carsten Nieder, Feng-Ming Kong, Jingbo Wang, Lindsay G. Jensen, Brent S. Rose, Arno J. Mundt, Ramesh Rengan, Charles R. Thomas, Nisha R. Patel, Michael L. Wong, Brandon J. Fisher, Larry C. Daugherty, Christin A. Knowlton, Michelle Kolton Mackay, Curt Heese, David Lightfoot, Lydia T. Komarnicky-Kocher, Fiori Alite, Christian Weiss, Claus Roedel, Patrizia Guerrieri, Paolo Montemaggi, Loren K. Mell, Stephan Mose, Brian F. Hasson, Darek Michalski, M. Saiful Huq, Claudia E. Rübe, Bradley J. Huth, Tony S. Quang, and Edward J. Gracely

Published
2013

50. Pneumoperitoneum

Author

Larry C. Daugherty, Brandon J. Fisher, Christin A. Knowlton, Michelle Kolton Mackay, David E. Wazer, Anthony E. Dragun, James H. Brashears, Lydia T. Komarnicky-Kocher, Fiori Alite, Feng-Ming Kong, Jingbo Wang, Filip T. Troicki, Jaganmohan Poli, Rene Rubin, Daniel Yeung, Jatinder Palta, Charlie Ma, Lu Wang, Stephan Mose, Felipe A. Calvo, Hedvig Hricak, Oguz Akin, Hebert Alberto Vargas, Daniel J. Indelicato, Robert H. Sagerman, Erik Limbergen, Yan Yu, Laura Doyle, Darek Michalski, M. Saiful Huq, Theodore E. Yaeger, Cheri Yaeger, Jay E. Reiff, Jo Ann Chalal, Lindsay G. Jensen, Loren K. Mell, Ramesh Rengan, Charles R. Thomas, Edward J. Gracely, John P. Christodouleas, Claudia E. Rübe, Paul J. Schilling, Tony S. Quang, Ari D. Brooks, T. Wiegel, D. Bottke, A. Ghazal, M. Schrader, Bradley J. Huth, and Curt Heese

Published
2013

Catalog

Books, media, physical & digital resources
See catalog results